Adam Camiel is currently serving as the Senior Director, Corporate Counsel at MapLight Therapeutics, Inc., a position held since October 2025. Previously, Adam held the role of Senior Associate at WilmerHale, focusing on Technology Transactions & Licensing from July 2023 to October 2025. Adam also served as Director, Corporate Counsel and Chief of Staff at Servier Pharmaceuticals between October 2020 and July 2023. Prior experience includes roles as Associate at McDermott Will & Emery, specializing in Health and Life Sciences Licensing and Collaborations, and Associate at Haug Partners LLP, focusing on life sciences commercial and antitrust litigation. Adam's background in the pharmaceutical industry includes positions such as Global Brand Lead for ONIVYDE at Shire and work in oncology strategy at Baxalta and competitive intelligence at Novartis Vaccines. Adam holds a Juris Doctor from Suffolk University Law School, an MBA with dual concentrations from Suffolk University - Sawyer Business School, and a Bachelor's Degree in Legal Studies and Global Business Management from Babson College, complemented by studies at HEC Paris in 2011.
This person is not in any teams
This person is not in any offices